KRAS mutations are considered to occur during initiation or early event in colorectal carcinogenesis [16, 17], but not in the malignant progression of CRC because it has been found in dysplastic lesions and adenomatous polyps, and such mutations alone are insufficient for the sustained growth of cancer. This evidence concerns the gene KRAS and cancer.